Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex®) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion
Annie Chan, Loh-Shan Leung, Mark S BlumenkranzDepartment of Ophthalmology, Stanford University School of Medicine, Stanford, CA, USAAbstract: Macular edema is a common cause of visual loss in patients with retinal vein occlusions. Ozurdex®, a dexamethasone intravitreal implant, has been...
Guardado en:
Autores principales: | Chan A, Leung LS, Blumenkranz MS |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8b8816c33df84f278ef61e305a1ab325 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Intravitreal bevacizumab in macular edema secondary to branch retinal vein occlusion: 12-month results
por: Thapa R, et al.
Publicado: (2012) -
Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results
por: Demir M, et al.
Publicado: (2011) -
The comparison of intravitreal triamcinolone and bevacizumab in patients with macular edema secondary to branch retinal vein occlusion
por: Gokce G, et al.
Publicado: (2014) -
Dexamethasone implant in retinal vein occlusions
por: Han SB, et al.
Publicado: (2016) -
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
por: Udaondo P, et al.
Publicado: (2011)